The filing also noted Smith's indirect ownership of 7,931 shares through a Charitable Remainder Unitrust. The company's market capitalization stands at $38.08 million, with a P/E ratio of 3.28, suggesting an attractive valuation relative to earnings. The company's market capitalization stands at $38.08 million, with a P/E ratio of 3.28, suggesting an attractive valuation relative to earnings.
The filing also noted Smith's indirect ownership of 7,931 shares through a Charitable Remainder Unitrust. The company's market capitalization stands at $38.08 million, with a P/E ratio of 3.28, suggesting an attractive valuation relative to earnings.
The filing also noted Smith's indirect ownership of 7,931 shares through a Charitable Remainder Unitrust.
In other recent news, Precision BioSciences (NASDAQ:DTIL) has made significant progress in its gene-editing trials. The company's shares soared following a successful clinical response in an infant treated for Ornithine Transcarbamylase (OTC) deficiency using Precision BioSciences' ARCUS gene editing platform. This promising development led BMO Capital to upgrade Precision BioSciences from Market Perform to Outperform.
The company also reported a robust financial position, with an estimated $108.5 million in cash, cash equivalents, and restricted cash as of December 31, 2024. This financial strength is projected to support the company's operations into the second half of 2026.
Furthermore, Precision BioSciences received approval for its Clinical Trial Application in Hong Kong for PBGENE-HBV, marking a significant milestone in the development of in vivo gene editing therapies. This approval allows the company to extend its ELIMINATE-B Phase I trial to Hong Kong, targeting chronic hepatitis B (HBV).
In relation to analyst notes, Precision BioSciences maintained its Market Perform rating and $34 target from BMO Capital, which emphasized the clinical development of PBGENE-HBV. These recent developments demonstrate Precision BioSciences' ongoing efforts to advance gene editing therapies and validate its ARCUS platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.